DA
AZN icon

Dillon & Associates’s AstraZeneca AZN Stock Holding History

Dillon & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.81M Buy
14,274
+1,292
+10% +$249K 0.39% 41
2025
Q4 		$2.39M Buy
12,982
+371
+3% +$65.1K 0.31% 41
2025
Q3 		$1.94M Buy
12,611
+13
+0.1% +$1.97K 0.25% 43
2025
Q2 		$1.76M Buy
12,598
+507
+4% +$71.1K 0.24% 45
2025
Q1 		$1.79M Sell
12,091
-3,045
-20% -$441K 0.27% 45
2024
Q4 		$2M Sell
15,136
-1,289
-8% -$180K 0.28% 45
2024
Q3 		$2.56M Buy
16,425
+3,506
+27% +$566K 0.36% 41
2024
Q2 		$2.02M Buy
12,919
+875
+7% +$132K 0.29% 46
2024
Q1 		$1.64M Buy
12,044
+423
+4% +$56K 0.26% 48
2023
Q4 		$1.56M Buy
11,621
+443
+4% +$57.6K 0.28% 49
2023
Q3 		$1.52M Buy
11,178
+737
+7% +$101K 0.29% 48
2023
Q2 		$1.5M Buy
10,441
+1,344
+15% +$198K 0.28% 51
2023
Q1 		$1.25M Buy
9,097
+923
+11% +$124K 0.25% 51
2022
Q4 		$1.11M Buy
8,174
+1,199
+17% +$150K 0.24% 52
2022
Q3 		$767K Buy
6,975
+1,651
+31% +$209K 0.18% 54
2022
Q2 		$703K Buy
5,324
+922
+21% +$121K 0.16% 53
2022
Q1 		$581K Buy
4,402
+1,069
+32% +$128K 0.11% 54
2021
Q4 		$387K Buy
+3,333
New +$392K 0.07% 59

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Dillon & Associates's AZN Position: Q1 2026 in Review

Dillon & Associates increased its AstraZeneca (AZN) stake by 10% in Q1 2026, buying an estimated $249K and bringing the position to 14,274 shares worth $2.81M. The position accounts for 0.39% of the portfolio, ranked #41.

Dillon & Associates first reported a position in AZN in Q4 2021 and has held it in 18 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Dillon & Associates held 14,274 shares of AstraZeneca worth $2.81M as of Q1 2026.
  • Dillon & Associates bought 1,292 AstraZeneca shares in Q1 2026, an estimated $249K.
  • AstraZeneca made up 0.39% of Dillon & Associates's portfolio in Q1 2026, its #41 holding.
  • Dillon & Associates first reported a position in AstraZeneca in Q4 2021 and has held it in 18 quarters since.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.